Friday will be a quiet day, according to the City diary, perhaps allowing greater attention on some of the London market’s smaller fry.
Among the macro data, the US will be the main focus, with industrial production and retail sales figures as various of the states order businesses to close their doors again to contain the spread of the coronavirus.
Among the small smattering of results, there are interims expected from AIM-listed biotech Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) and Westminster Group PLC (LON:WSG), the security and technology group.
Verona last month raised a whopping US$200mln from new and existing investors to fund the clinical development of its breakthrough treatment for chronic obstructive pulmonary disease (COPD).
Back in May, the company was given the regulatory green light for two phase III studies of the nebulised formulation of its COPD drug, following a meeting with the US Food & Drug Administration where guidance was given on dosing, primary and secondary endpoints, patient population and study design.
Over at Westminster, the company said in a trading update last month that revenues in the first half of the year had jumped by around a quarter in spite of the coronavirus pandemic.
It revealed that half-year revenues were up 24% with the company saying it made a profit, the precise quantum of which will be revealed this week.
Significant announcements expected on Friday, August 14:
Economic data: US retail sales, US industrial production